175 related articles for article (PubMed ID: 29207175)
41. Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression is Associated with Tumor Grade in Head and Neck Cancer.
Chang CH; Yen MC; Liao SH; Hsu YL; Lai CS; Chang KP; Hsu YL
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28718842
[TBL] [Abstract][Full Text] [Related]
42. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
43. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
[TBL] [Abstract][Full Text] [Related]
44. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
[TBL] [Abstract][Full Text] [Related]
45. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
46. Aberrant
Bjerre MT; Strand SH; Nørgaard M; Kristensen H; Rasmussen AK; Mortensen MM; Fredsøe J; Mouritzen P; Ulhøi B; Ørntoft T; Borre M; Sørensen KD
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866497
[TBL] [Abstract][Full Text] [Related]
47. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
48. Downregulation of N-myc downstream regulated gene 1 caused by the methylation of CpG islands of NDRG1 promoter promotes proliferation and invasion of prostate cancer cells.
Li Y; Pan P; Qiao P; Liu R
Int J Oncol; 2015 Sep; 47(3):1001-8. PubMed ID: 26202882
[TBL] [Abstract][Full Text] [Related]
49. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
50. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
51. Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression.
Huang DY; Lin YT; Jan PS; Hwang YC; Liang ST; Peng Y; Huang CY; Wu HC; Lin CT
J Pathol; 2008 Mar; 214(4):445-55. PubMed ID: 18085523
[TBL] [Abstract][Full Text] [Related]
52. Methylation-mediated expression of SPARC is correlated with tumor progression and poor prognosis of breast cancer.
Li XL; Li JL; Qiu DJ; Ma L
Neoplasma; 2022 Jul; 69(4):794-806. PubMed ID: 35400166
[TBL] [Abstract][Full Text] [Related]
53. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
54. Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer.
Liu JW; Nagpal JK; Jeronimo C; Lee JE; Henrique R; Kim MS; Ostrow KL; Yamashita K; van Criekinge V; Wu G; Moon CS; Trink B; Sidransky D
Prostate; 2008 Mar; 68(4):418-26. PubMed ID: 18196513
[TBL] [Abstract][Full Text] [Related]
55. Expression of secreted protein acidic and rich in cysteine is an independent prognostic indicator of a poor clinical outcome in oropharyngeal carcinoma patients.
Yoshida S; Wakisaka N; Kondo S; Moriyama-Kita M; Hirai N; Endo K; Tsuji A; Nakanishi Y; Murono S; Yoshizaki T
Acta Otolaryngol; 2016; 136(2):189-94. PubMed ID: 26523779
[TBL] [Abstract][Full Text] [Related]
56. Downregulation of EphA5 by promoter methylation in human prostate cancer.
Li S; Zhu Y; Ma C; Qiu Z; Zhang X; Kang Z; Wu Z; Wang H; Xu X; Zhang H; Ren G; Tang J; Li X; Guan M
BMC Cancer; 2015 Jan; 15():18. PubMed ID: 25609195
[TBL] [Abstract][Full Text] [Related]
57. Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Pan J; Chen Y; Mo C; Wang D; Chen J; Mao X; Guo S; Zhuang J; Qiu S
PLoS One; 2014; 9(3):e92815. PubMed ID: 24664224
[TBL] [Abstract][Full Text] [Related]
58. DNA methylation and aberrant expression of Sprouty1 in human prostate cancer.
Kwabi-Addo B; Ren C; Ittmann M
Epigenetics; 2009 Jan; 4(1):54-61. PubMed ID: 19164898
[TBL] [Abstract][Full Text] [Related]
59. Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21.
Liang Z; Mou Q; Pan Z; Zhang Q; Gao G; Cao Y; Gao Z; Pan Z; Feng W
Med Oncol; 2019 May; 36(6):56. PubMed ID: 31089825
[TBL] [Abstract][Full Text] [Related]
60. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
